SASU NEMERA SERVICES

With our extensive experience in intranasal delivery, we offer reliable, easy to use and safe nasal vaccine solutions*. The concept device is constituted with a nozzle, a dose divider, and a luer lock syringe. It contains two-doses, allowing vaccine delivery for each nostril.

Our portfolio of disposable pens includes variable and fixed dose devices for automatic and manual drug administration, combining modern design with high intuitiveness of use for multidose therapies. Nemera offers three disposable pen injector development platforms with wide customization and drug capabil...

Implants are fragile and insertion into the body requires caution. Nemera developed a portfolio of devices to deliver implants with integrated needlestick protection. As implants can vary a lot, we support your projects and explore design attributes that will increase the user experience such as improved h...

Ergonomic, market-proven reusable pen injectors Our spring-assisted reusable pens lower the force necessary to administer the dose for patient’s ease-of-use. Thanks to its ergonomic design, patients can easily reach the trigger button for an enhanced injection experience. This platform offers a high range ...

Safe'n'Spray: the smart electronic concept device with locking features Some drugs such as strong painkillers called opioids (e.g. Fentanyl) can cause respiratory depression in case of overdose, and can be fatal. That’s why patients must rely on a device with locking and child-resistant features for multid...

The Innovation in Connectivity Roundtable originally aired as part of Pharmapack Europe 2021 Part 1 of this session includes three presentations: Patient Journey Driven Considerations for Integrating Digital Health for Combination Products The importance of utilizing applied ethnography and other primary research methods to understand the patient journey as the foundation for integrating digital health into a device/combination product development initiative. Considering patient needs in the context of a larger ecosystem including providers, payers, and regulators to develop a robust plan with respect to connectivity and digital health. Examples of how this understanding is applied across the combination product development journey through organic development, utilization of platform devices, or as a lifecycle management enchantments while optimizing the user experience resulting in safe, effective, and differentiated combination products. Mark Tunkel, Global Category Director for Insight Innovation, Nemera Electronic Product Information: A Case Study on Medicine Labelling for the Visually Impaired The Electronic Product Information Initiative for Medicines (ePI) aim to ease the accessibility of product information to everyone, including visually impaired patients. The GS1 Digital Link aim to provide a single barcode for identification, brand protection, and access to product information for patients. Our lecture will illustrate how the existing Datamatrix on packaging could be leveraged, today, by everyone, including visually impaired users, to access a tailored and relevant information. Laurent Tonnelier, CEO, mobiLead - xTag Lise Wagner, Accessibility Specialist and User Expert, OKEENEA Traceability of Medicines: from Finished Product to Unit Dose Delivery Challenges for B2B Supply Chain stakeholders Regulations: a global overview What about B2C Nathalie Wardé, CEO & Founder, D4P pharma Join the above speakers and moderator Lionel Jeannin, Group Head Oral Packaging & Delivery Systems, Novartis Pharma AG for the live panel discussion that followed in the Innovation in Connectivity Roundtable pt. 2